Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma

Although tyrosine kinase inhibitors (TKIs) have demonstrated significant efficacy in advanced lung adenocarcinoma (LUAD) patients with pathogenic alterations in EGFR, most patients develop acquired resistance to these agents via mechanisms enabling the sustained activation of the PI3K and MAPK oncog...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Tohmé, Rita, Izadmehr, Sudeh, Gandhe, Sai, Tabaro, Giancarlo, Vallabhaneni, Sanjay, Thomas, Ava, Vasireddi, Neal, Dhawan, Neil S., Ma’ayan, Avi, Sharma, Neelesh, Galsky, Matthew D., Ohlmeyer, Michael, Sangodkar, Jaya, Narla, Goutham
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6478418/
https://ncbi.nlm.nih.gov/pubmed/30830869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.125693
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados